Generali Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.6M Buy
81,938
+1,452
+2% +$312K 0.37% 60
2026
Q1
$17.5M Sell
80,486
-5,924
-7% -$1.31M 0.37% 62
2025
Q4
$19.7M Buy
86,410
+8,288
+11% +$1.89M 0.4% 50
2025
Q3
$18.1M Sell
78,122
-6,172
-7% -$1.26M 0.39% 58
2025
Q2
$15.6M Buy
84,294
+245
+0.3% +$45.5K 0.36% 60
2025
Q1
$17.6M Sell
84,049
-24,502
-23% -$4.76M 0.43% 42
2024
Q4
$19.3M Buy
+108,551
New +$20M 0.49% 38

Other funds holding ABBV

Generali Asset Management's ABBV Position: Q2 2026 in Review

Generali Asset Management increased its AbbVie (ABBV) stake by 1.8% in Q2 2026, buying an estimated $312K and bringing the position to 81,938 shares worth $20.6M. The position accounts for 0.37% of the portfolio, ranked #60.

Generali Asset Management first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Generali Asset Management held 81,938 shares of AbbVie worth $20.6M as of Q2 2026.
  • Generali Asset Management bought 1,452 AbbVie shares in Q2 2026, an estimated $312K.
  • AbbVie made up 0.37% of Generali Asset Management's portfolio in Q2 2026, its #60 holding.
  • Generali Asset Management first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.